Skip to main content

Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical operations

Tampere Heart Hospital Finland

October 19, 2023

Sustainability roadmap addresses opportunities to reduce carbon emissions in patient throughput, technology use, and use of consumables

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital – Tampere University Hospital’s (Finland) environmental sustainability, including a deep assessment of the interventional cardiology space and evaluation of its carbon footprint. The results of the analysis have been translated into a joint action plan that will help Heart Hospital accelerate its decarbonization efforts in line with Finland’s world-leading commitment to reach net zero emissions by 2035.

“Sustainability is an integral part of Tampere Heart Hospital strategy. We are aware that hospitals generate a significant amount of waste daily and consume a lot of energy. We want to contribute to the development of environmental responsibility in healthcare,” said Pasi Lehto CEO and Chief Medical Officer at Heart Hospital.

“We want to ascertain where we are now and how we can further accelerate our transition towards net zero,” said Aki Haukilahti, CFO at Tampere Heart Hospital. “Our long-standing relationship with Philips and their industry leadership in driving sustainable healthcare made them a natural partner to help audit our emissions and develop a roadmap for the future.”

Part of an existing 15-year strategic managed services agreement between Heart Hospital and Philips, the analysis involved a detailed lifecycle assessment of the hospital’s medical equipment, supply chain, and clinical operations. The analysis provided a baseline carbon footprint for Tampere Heart Hospital’s interventional cardiology service and facilitated the identification of opportunities to enhance patient throughput and equipment utilization to reduce future emissions. Top findings included optimization of the hospital’s patient care pathways to improve efficiency and materials use, and opportunities for reducing inbound airfreight, reducing waste and improving waste separation. 

“At Philips, we are committed to driving systemic change towards more sustainable and equitable patient care. Through our healthcare technology and expertise, we can help healthcare providers to support their patients with as little impact on the environment as possible,” said Robert Metzke, Global Head of Sustainability at Philips. “This valuable and informative analysis with Tampere Heart Hospital, a pioneering and leading global cardiac care provider, will help achieve our shared goal of taking care of patients and the planet at the same time.”  

In addition to a detailed analysis of carbon emissions associated with the hospital’s medical equipment and supply chain, Philips’ analysis of the hospital’s current emissions also encompasses clinical operations in key patient care pathways.

This sustainability program with Tampere Heart Hospital follows similar analyses conducted by Philips earlier in 2023 at Vanderbilt University Medical Center (Nashville, USA) and the private biomedical research and clinical care provider Champalimaud Foundation (Lisbon, Portugal), aimed at reducing the carbon footprint of their diagnostic imaging.

Globally, healthcare systems have a significant climate footprint and make a major contribution to the climate crisis [1]. Building on decades of experience reducing energy consumption, waste, and materials and substance usage, Philips has operated globally carbon-neutral since 2020, embedding EcoDesign principles and circular business models into its innovation processes and ways of working. The company offers a range of health technologies and innovations that help reduce healthcare providers’ impact on the environment. For example, its Philips Spectral CT 7500 uses 62.5% less energy [2], and the Philips MR – Ingenia Ambition 1.5T, which uses a breakthrough design where the magnetic components are completely sealed and only need seven liters of helium over its lifetime compared to roughly 1,500 liters with other Philips systems [3]. Additionally, with Philips MR SmartSpeed, the Ingenia Ambition 1.5T uses up to 53% less power per patient scan [3].

Read more here on how Philips is partnering with hospitals around the world to drive sustainable healthcare.

[1] https://noharm-global.org/sites/default/files/documents-files/5961/HealthCaresClimateFootprint_092319.pdf
[2] When compared to an equivalent CT model of one of the industry leaders
[3] Applicable to Ambition S. Philips SmartSpeed power consumption versus Philips SENSE based scanning. Based on COCIR and in-house simulated environment. Results can vary based on site conditions.

For further information, please contact:

Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.